AndhraNews.net
Home » Business News » 2012 » July » July 19, 2012

Protein Kinase Inhibitors, Monoclonal Antibodies & Vaccines Therapeutic Classes Dominate Late-Stage Oncology Pipeline


July 19, 2012 - Rockville, MD

MarketResearch.com has announced the addition of the new report "Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline," to their collection of Pharmaceuticals market reports. For more information, visit http://www.marketresearch.com/GBI-Research-v3759/Novel-Therapies-Oncology-Protein-Kinase-7061034/

GBI Research, the leading business intelligence provider, has released its latest research, "Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline" which provides insights into the global oncology pipeline. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth pipeline analysis of the breast cancer, ovarian cancer, non-small cell lung cancer, non-Hodgkin lymphoma, prostate cancer, cervical cancer, colorectal cancer and head and neck cancer segments. The report examines promising pipeline molecules and provides the expected market revenues from the year of launch. The report also includes analysis of mergers and acquisitions (M&A) and licensing agreements that have taken place in the global oncology market.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts.

GBI Research also analyzed the promising pipeline molecules that are expected to be launched during the forecast period (2012-2018). The molecules are Avastin, T-DM1, Afinitor, Iniparib, Afatinib, V503, Tykerb and Thera CIM. The launch of promising molecules is projected to add $2,979m in revenues by 2018. The novel molecules are expected to increase progression free survival, providing a better treatment option to cancer patients. The molecules are expected to address the safety and unmet needs. GBI Research analyzed 63 M&A deals, 95 licensing deals and 67 R&D collaboration agreements that took place during 2007-2011 and found that competitive activity is increasing in the oncology therapeutics market.

For more information, visit http://www.marketresearch.com/GBI-Research-v3759/Novel-Therapies-Oncology-Protein-Kinase-7061034/

About MarketResearch.com

MarketResearch.com is the leading provider of global market intelligence products and services. With research reports from more than 720 top consulting and advisory firms, MarketResearch.com offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. Moreover, MarketResearch.com's Research Specialists have in-depth knowledge of the publishers and the various types of reports in their respective industries and are ready to provide research assistance. For more information, call Veronica Franco at 240-747-3016 or visit http://www.marketresearch.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Veronica Franco
MarketResearch.com
Email Contact
240.747.3016

MarketWire

Comment on this story

Share